Table 2. Randomized clinical trials (Phase 3) comparing upfront debulking surgery followed by adjuvant chemotherapy with interval debulking surgery (IDS) after neoadjuvant chemotherapy in cases of advanced epithelial ovarian cancer.
| Study | Criteria | No of patients | OS (months | PFS (months) | Complete cytoreduction | Optimal cytoreduction |
|---|---|---|---|---|---|---|
| EORTC 55971 | Stage IIIC–IV | UDS-ACT 336 | 30 both groups | 12 both groups | UDS-ACT 19% | Not available |
| NACT-IDS 334 | NACT-IDS 51% | |||||
| The CHemotherapyORUpfront Surgery (CHORUS) trial | Stage* III–IV | UDS-ACT 276 | 23 both groups | 12 both groups | UDS-ACT 17% | Not available |
| NACT-IDS 274 | NACT-IDS 43% | |||||
| JCOG 0602 trial | Stage IIIC–IV | UDS-ACT 149 | UDS ACT 49 | UDS ACT 15.1 | UDS-ACT 12% | UDS-ACT 37% |
| NACT-IDS 152 | NACT IDS 44.3 | NACT IDS 16.4 | NACT-IDS 64% | NACT-IDS 82% | ||
| SCORPION trial | Stage IIIC–IV Fagotti score 8 to 12 | UDS-ACT 55 | Not available | Not available | UDS-ACT 46% | UDS-ACT 92.8% |
| NACT-IDS 55 | NACT-IDS 58% | NACT-IDS 100% | ||||
| TRUST trial, NCT02828618 | Stage IIIB–IVB | 772 | On-going trial | |||
| Results are expected in 2024 | ||||||
*, no histologic confirmation. UDS, upfront debulking surgery; ACT, adjuvant chemotherapy; NACT, neoadjuvant chemotherapy; IDS, interval debulking surgery; OS, median overall survival; PFS, median progression-free survival.